EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
PISA, Italy, May 29, 2023 /PRNewswire/ -- Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European and international markets. The key active agent developed by EffRx is buffered soluble alendronate which belongs to a class of non-hormonal pharmaceuticals known as bisphosphonates. This medication has been distributed in Italy by Abiogen Pharma since 2014 under a licence agreement.
Dubai, Moscow, Ljubljana, Sao Paulo, Zurich, London, November 14, 2022 – WODA members (EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC G, and Vector Pharma), are pleased to announce the addition of Decisive Consulting to the Alliance network. With a highly experienced team, Decisive Consulting has capabilities to solve many challenging issues related to pricing, market access, portfolio design and launch strategy.
EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC, and Vector Pharma, announced the newly formed World Orphan Drug Alliance (WODA). WODA aims to provide comprehensive support to pharmaceutical and biotech companies with rare diseases, oncology and highly specialized therapeutics portfolio, starting from named patient programs through to full commercialization.
FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Efmody® in Switzerland.
FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Alkindi® for the treatment of paediatric adrenocortical insufficiency (AI).